Skip to main content
Top
Gepubliceerd in: Quality of Life Research 3/2022

14-07-2021

Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors

Auteurs: Cuc Thi Thu Nguyen, Binh Thanh Nguyen, Thuy Thi Thu Nguyen, Fabio Petrelli, Stefania Scuri, Iolanda Grappasonni

Gepubliceerd in: Quality of Life Research | Uitgave 3/2022

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

This study aims to evaluate the quality of life (QoL) of chronic myeloid leukemia (CML) patients prescribed with nilotinib as a second-line therapy and explores the influential factors.

Methods

A multicenter retrospective survey was conducted via face-to-face interviews based on the EORTC QLQ-C30 questionnaire. A total of 121 adult CML patients resistant to imatinib and used nilotinib for at least 3 months were enrolled. The influential features were assessed by multiple linear regression models.

Results

Patients had the mean age of 47.49 (SD = 13.67) years, dominated by middle-aged and male groups. The mean scores of functions ranged from 75 to 83, and those of symptoms were from 5 to 28, with the highest of fatigue (28.28), insomnia (22.87), and pain (21.07). The mean global health status/QoL score was 67.70 (SD = 16.80) with considerable financial difficulties (52.34 (SD = 32.15)). Male patients reported higher functional scores and fewer symptoms compared with female patients. All aspects of QoL became worse with increasing age. Besides age and gender, level of education, duration of nilotinib usage, and comorbidities were also significantly influential factors in many QoL domains. A predicted model for expected mean scores of QoL domains was built based on these factors.

Conclusions

The CML patients treated with nilotinib had the above-moderate QoL scores, a light decrease of functional scores, great financial difficulties, and still experienced symptoms. Strategies and more therapeutic considerations to enhance QoL for CML patients targeted toward women, the old, low educational level, and long duration of nilotinib usage, and many comorbidities are needed in the setting.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
2.
go back to reference Gambacorti-Passerini, C., Antolini, L., Mahon, F. X., Guilhot, F., Deininger, M., Fava, C., et al. (2011). Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. Journal of the National Cancer Institute, 103(7), 553–561. https://doi.org/10.1093/jnci/djr060CrossRefPubMed Gambacorti-Passerini, C., Antolini, L., Mahon, F. X., Guilhot, F., Deininger, M., Fava, C., et al. (2011). Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. Journal of the National Cancer Institute, 103(7), 553–561. https://​doi.​org/​10.​1093/​jnci/​djr060CrossRefPubMed
5.
go back to reference DeRemer, D. L., Ustun, C., & Natarajan, K. (2008). Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clinical Therapeutics, 30(11), 1956–1975.CrossRef DeRemer, D. L., Ustun, C., & Natarajan, K. (2008). Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clinical Therapeutics, 30(11), 1956–1975.CrossRef
6.
go back to reference Saglio, G., Kim, D.-W., Issaragrisil, S., Le Coutre, P., Etienne, G., Lobo, C., et al. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362(24), 2251–2259.CrossRef Saglio, G., Kim, D.-W., Issaragrisil, S., Le Coutre, P., Etienne, G., Lobo, C., et al. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362(24), 2251–2259.CrossRef
10.
go back to reference Huguet, F., Cayuela, J. M., Cambier, N., Carpentier, N., Tindel, M., Violet, I., et al. (2019). Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: A prospective observational study in daily clinical practice. British Journal of Haematology, 187(5), 615–626. https://doi.org/10.1111/bjh.16145CrossRefPubMed Huguet, F., Cayuela, J. M., Cambier, N., Carpentier, N., Tindel, M., Violet, I., et al. (2019). Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: A prospective observational study in daily clinical practice. British Journal of Haematology, 187(5), 615–626. https://​doi.​org/​10.​1111/​bjh.​16145CrossRefPubMed
11.
go back to reference Cortes, J. E., Lipton, J. H., Miller, C. B., Busque, L., Akard, L. P., Pinilla-Ibarz, J., et al. (2016). Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH Study. Clinical Lymphoma, Myeloma & Leukemia, 16(5), 286–296. https://doi.org/10.1016/j.clml.2016.02.002CrossRef Cortes, J. E., Lipton, J. H., Miller, C. B., Busque, L., Akard, L. P., Pinilla-Ibarz, J., et al. (2016). Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH Study. Clinical Lymphoma, Myeloma & Leukemia, 16(5), 286–296. https://​doi.​org/​10.​1016/​j.​clml.​2016.​02.​002CrossRef
13.
go back to reference Sacha, T., Gora-Tybor, J., Wasak-Szulkowska, E., Kyrcz-Krzemien, S., Medras, E., Becht, R., et al. (2017). Quality of Life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second-line therapy: A multicenter prospective observational study. Clinical Lymphoma, Myeloma & Leukemia, 17(5), 283–295. https://doi.org/10.1016/j.clml.2017.01.001CrossRef Sacha, T., Gora-Tybor, J., Wasak-Szulkowska, E., Kyrcz-Krzemien, S., Medras, E., Becht, R., et al. (2017). Quality of Life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second-line therapy: A multicenter prospective observational study. Clinical Lymphoma, Myeloma & Leukemia, 17(5), 283–295. https://​doi.​org/​10.​1016/​j.​clml.​2017.​01.​001CrossRef
15.
go back to reference Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376. https://doi.org/10.1093/jnci/85.5.365CrossRefPubMed Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376. https://​doi.​org/​10.​1093/​jnci/​85.​5.​365CrossRefPubMed
16.
go back to reference Zawisza, K., Tobiasz-Adamczyk, B., Nowak, W., Kulig, J., & Jedrys, J. (2010). Validity and reliability of the quality of life questionnaire (EORTC QLQ C30) and its breast cancer module (EORTC QLQ BR23). Ginekologia Polska, 81(4), 262–267.PubMed Zawisza, K., Tobiasz-Adamczyk, B., Nowak, W., Kulig, J., & Jedrys, J. (2010). Validity and reliability of the quality of life questionnaire (EORTC QLQ C30) and its breast cancer module (EORTC QLQ BR23). Ginekologia Polska, 81(4), 262–267.PubMed
17.
18.
go back to reference Kyriaki, M., Eleni, T., Efi, P., Ourania, K., Vassilios, S., & Lambros, V. (2001). The EORTC core quality of life questionnaire (QLQ-C30, version 3.0) in terminally ill cancer patients under palliative care: validity and reliability in a Hellenic sample. International Journal of Cancer, 94(1), 135–139. https://doi.org/10.1002/ijc.1439CrossRefPubMed Kyriaki, M., Eleni, T., Efi, P., Ourania, K., Vassilios, S., & Lambros, V. (2001). The EORTC core quality of life questionnaire (QLQ-C30, version 3.0) in terminally ill cancer patients under palliative care: validity and reliability in a Hellenic sample. International Journal of Cancer, 94(1), 135–139. https://​doi.​org/​10.​1002/​ijc.​1439CrossRefPubMed
19.
go back to reference Velikova, G., Coens, C., Efficace, F., Greimel, E., Groenvold, M., Johnson, C., et al. (2012). Health-Related Quality of Life in EORTC clinical trials—30 years of progress from methodological developments to making a real impact on oncology practice. European Journal of Cancer Supplements, 10(1), 141–149. https://doi.org/10.1016/S1359-6349(12)70023-XCrossRef Velikova, G., Coens, C., Efficace, F., Greimel, E., Groenvold, M., Johnson, C., et al. (2012). Health-Related Quality of Life in EORTC clinical trials—30 years of progress from methodological developments to making a real impact on oncology practice. European Journal of Cancer Supplements, 10(1), 141–149. https://​doi.​org/​10.​1016/​S1359-6349(12)70023-XCrossRef
20.
go back to reference R Core Team. (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing. R Core Team. (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing.
21.
go back to reference Scott, N. W., Fayers, P., Aaronson, N. K., Bottomley, A., de Graeff, A., Groenvold, M., et al. (2008). EORTC QLQ-C30 reference values manual. Scott, N. W., Fayers, P., Aaronson, N. K., Bottomley, A., de Graeff, A., Groenvold, M., et al. (2008). EORTC QLQ-C30 reference values manual.
24.
31.
go back to reference Au, W. Y., Caguioa, P. B., Chuah, C., Hsu, S. C., Jootar, S., Kim, D.-W., et al. (2009). Chronic myeloid leukemia in Asia. International Journal of Hematology, 89(1), 14–23.CrossRef Au, W. Y., Caguioa, P. B., Chuah, C., Hsu, S. C., Jootar, S., Kim, D.-W., et al. (2009). Chronic myeloid leukemia in Asia. International Journal of Hematology, 89(1), 14–23.CrossRef
33.
go back to reference Kuan, J. W., & Melaine Michael, S. (2018). The epidemiology of chronic myeloid leukaemia in southern Sarawak, Borneo Island. Medical Journal of Malaysia, 73(2), 78–85. Kuan, J. W., & Melaine Michael, S. (2018). The epidemiology of chronic myeloid leukaemia in southern Sarawak, Borneo Island. Medical Journal of Malaysia, 73(2), 78–85.
36.
go back to reference Quinten, C., Coens, C., Ghislain, I., Zikos, E., Sprangers, M. A., Ringash, J., et al. (2015). The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. European Journal of Cancer, 51(18), 2808–2819. https://doi.org/10.1016/j.ejca.2015.08.027CrossRefPubMed Quinten, C., Coens, C., Ghislain, I., Zikos, E., Sprangers, M. A., Ringash, J., et al. (2015). The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. European Journal of Cancer, 51(18), 2808–2819. https://​doi.​org/​10.​1016/​j.​ejca.​2015.​08.​027CrossRefPubMed
46.
go back to reference Efficace, F., Baccarani, M., Breccia, M., Saussele, S., Abel, G., Caocci, G., et al. (2014). International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: The EORTC QLQ-CML24. Quality of Life Research, 23(3), 825–836. https://doi.org/10.1007/s11136-013-0523-5CrossRefPubMed Efficace, F., Baccarani, M., Breccia, M., Saussele, S., Abel, G., Caocci, G., et al. (2014). International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: The EORTC QLQ-CML24. Quality of Life Research, 23(3), 825–836. https://​doi.​org/​10.​1007/​s11136-013-0523-5CrossRefPubMed
Metagegevens
Titel
Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors
Auteurs
Cuc Thi Thu Nguyen
Binh Thanh Nguyen
Thuy Thi Thu Nguyen
Fabio Petrelli
Stefania Scuri
Iolanda Grappasonni
Publicatiedatum
14-07-2021
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 3/2022
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-021-02952-9

Andere artikelen Uitgave 3/2022

Quality of Life Research 3/2022 Naar de uitgave